Back to search results

Bumetanide for Alzheimer's Disease

This study is investigating whether bumetanide, a common diuretic (water pill) already approved by the FDA for conditions like swelling and high blood pressure, could help people with Alzheimer's disease. Researchers are testing bumetanide against a placebo (an inactive pill) to see if it causes any side effects over six months. You might be able to join if you are 50 to 85 years old and have mild cognitive impairment or mild dementia due to Alzheimer's disease. The study is currently unclear on its recruitment status and aims to enroll 40 participants.

Study design
This study is interventional and plans to enroll 40 participants. It compares bumetanide to a placebo.
What's involved
You would need to be willing and able to complete all study aspects, including assessments, neuropsychological testing, and MRI scans.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, treatment-related adverse events, is measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06052163

Bumetanide in Patients With Alzheimer's Disease

Recruiting
PHASE2Ages 50–85InterventionalTreatment
Stanford University
~40 participants
Updated 2026-01-14 on ClinicalTrials.gov
What's tested:BumetanidePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-Related Adverse Events
Measured over 6 months

Conditions

Alzheimer Disease

Explore related trials

Alzheimer's Disease

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Kyan Younes, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Mina L Kim
[email protected]
(650) 387-1559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Mild cognitive impairment or mild dementia due to Alzheimer's disease.
Alzheimer's disease medications are planned to remain stable throughout.
Willingness and ability to complete all aspects of the study including assessments, neuropsychological testing, and MRI.

Exclusion

Clinically significant abnormalities in screening laboratory tests
Chronic liver disease
Renal insufficiency
Poorly managed hypertension
Participants taking the following concomitant medications, based on the current Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs with nephrotoxic potential, probenecid, and indomethacin.

What this trial measures

  • Incidence of Treatment-Related Adverse Events6 months

    Number of participants with adverse events including clinical signs and symptoms, change in vital signs, ECGs, laboratory safety tests, and suicidality assessments.